Skip to Main Content

David Matuskey, MD

Associate Professor of Radiology and Biomedical Imaging; Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) Center

Research Summary

I am a board certified psychiatrist and neuropsychiatrist with research work that has been translational in nature and focused on elucidating the underlying pathology of conditions such as Autism Spectrum Disorder, substance abuse and Parkinson's disease with an aim to find effective clinical treatments guided by molecular neuroimaging. Studies have included using in-vivo PET imaging to investigate the role of receptors such as dopamine D3, serotonin 1B and 6, MGlur5 and kappa, neuroinflammation, and most recently, synaptic density (SV2A) in clinical and nonclinical populations. Ongoing interests include imaging addiction and neuropsychiatric disorders and demographic, social and environmental factors influencing our brain.

Coauthors

Research Interests

Autistic Disorder; Mental Disorders; Parkinson Disease; Social Class; Meditation; Essential Tremor; Molecular Imaging; Frontotemporal Dementia; Neuropsychiatry; Neuroimaging; Addiction Medicine

Public Health Interests

Global Health; Mental Health

Selected Publications

Clinical Trials

ConditionsStudy Title
Addictive BehaviorsBrain Imaging and Synaptic Plasticity
Mental Health & Behavioral ResearchM1 Schizophrenia PET Study
Alzheimer's DiseaseA Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
Diseases of the Nervous SystemMeditation and Synaptic Density
Diseases of the Nervous SystemStudy of Safety and of the Mechanism of BLZ945 in ALS Patients
Mental Health & Behavioral Research; Alzheimer's DiseaseKetamine for the Treatment of Depression in Parkinson's Disease
Alzheimer's DiseaseAHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Alzheimer's DiseaseA Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Men's Health; Women's HealthEvaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
Alzheimer's DiseaseA Randomized, Double-Blind, Placebo controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease
Mental Health & Behavioral ResearchHPA axis function in the brains of PTSD, Trauma Exposed, or Otherwise Healthy research participants utilizing PET and MRI imaging
Diseases of the Endocrine System; Genetics - AdultA Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)
Diseases of the Nervous System; HIV/AIDS; Infectious Diseases; COVID-19 Inpatient; COVID-19 OutpatientHIV Associated Reservoirs and Comorbidities (The HARC Plus Study)
Addictive BehaviorsPET Imaging of Microglia with [11C]PBR28 in Opioid Dependent and Healthy Control Subjects
Mental Health & Behavioral ResearchEligibility for Participation in Neuroimaging Studies
Diseases of the Lung; Diseases of the Respiratory SystemsSafety, Tolerability, Kinetics, and Repeatability of the Novel LPA1 PET Ligand 18F-BMS-986327
Child Development & AutismPET Imaging Study for Young Adults with ASD
Diseases of the Nervous SystemImaging the Dopamine Transporter in Parkinson's Disease
Addictive Behaviors; Mental Health & Behavioral Research; Tobacco AddictionImaging smoking-induced dopamine release utilizing PET imaging and nicotine patches
Mental Health & Behavioral ResearchMechanistic Evaluation of Guanfacine on Drinking Behavior